Idraparinux sodium: Anticoagulant factor Xa inhibitor

Drugs of the Future

Volumn 27, Issue 7, 2002, Pages 639-644

  Diaz Ricart, M ^a   Del Fresno, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; IDRAPARINUX; PENTASACCHARIDE; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG EMBOLISM; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; REVIEW;

EID: 0036659943     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.07.687868     Document Type: Review

References (15)

1. Westerduin, P., van Boeckel, C.A.A., Basten, J.E.M. et al. Feasible synthesis and biological properties of six 'non-glycosamino' glycan analogues of the antithrombin III binding heparin pentasaccharide. Bioorg Med Chem 1994, 2: 1267-80.
2. Petitou, M., van Boeckel, C.A.A. (Akzo Nobel N.V.; Sanofi-Synthélabo). Sulfated glycosaminoglycanoid derivs. of the heparin sulfate type. EP 0454220, JP 1992225994, US 5378829, US 5382570, US 5529985, US 5773605.
3. Petitou, M., van Boeckel, C.A.A. (Akzo Nobel N.V.; Sanofi-Synthélabo). Sulfated glycosaminoglycanoid derivs. EP 0529715.
4. Morrissey, J.H. Tissue factor: An enzyme cofactor and a true receptor. Thromb Haemost 2001, 86: 66-74.
5. Gresele, P., Agnelli, G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002, 23: 25-32.
6. Reverter, J.C. Fondaparinux sodium. Drugs Fut 2002, 27: 122- 31.
7. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet 2002, 359: 1721-6.
8. Van Amsterdam, R.G.M., Vogel, G.M.T., Visser, A., Kop, W.J., Buiting, M.T., Meuleman, D.G. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 1995, 15: 495-503.
9. Herbert, J.M., Herault, J.P., Bernat, A., van Amsterdam, R.G.M., Lormeau, J.C., Petitou, M., van Boeckel, C., Hoffmann, P., Meulerman, D.G. Biochemical and pharmacological properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91: 4197-205.
10. Ahmad, S., Jeske, W.P., Walenga, J.M., Hoppensteadt, D.A., Wood, J.J., Herbert, J.M., Messmore, H.L., Fareed, J. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999, 5: 259-66.
11. Herault, J.P., Perrin, B., Jongbloet, C., Pflieger, A.M., Bernat, A., Herbert, J.M. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats. Thromb Haemost 2000, 84: 668-74.
12. Vogel, G.M.T., Smit, M.J., Princen, A.W.M., van Dinther, T.G., Boveé-v.d. Pash, J.G.H.W., Meuleman, D.G. Continuous factor Xa inhibitory activity by SanOrg34006 results in high potency after thrombolysis of an occlusive thrombus in an experimental model in rabbits. Thromb Haemost 2001, Suppl.: Abst P1410.
13. Herault, J.P., Bono, F., Avril, C., Schaeffer, P., Herbert, J.M. Activation of human vascular endothelial cells by factor Xa: Effect of specific inhibitors. Biochem Pharmacol 1999, 57: 603-10.
14. Faaij, R.A., Burggraaf, J., Schoemaker, R.C., van Amsterdam, R.G.M., Cohen, A.F. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SanOrg 34006 in healthy young male volunteers. Thromb Haemost 1999, Suppl.: Abst 2709.
15. Faaij, R.A., Burggraaf, J., Schoemaker, R.C., van Amsterdam, R.G.M., Cohen, A.F. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SanOrg 34006 in healthy male and female elderly volunteers. Thromb Haemost 1999, Suppl.: Abst 1547.